Q-omics provides the consensus-scored GPR182 profile across patient tissues and cancer cell-line models. GPR182 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, GPR182 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, GPR182 RNA expression shows 12,885 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight SCLC, KIRC, and ESCA as cancer lineages where GPR182 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR182 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR182 survival associations across molecular data types. GPR182 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR182 RNA expression–survival associations across cancer types. High GPR182 expression shows unfavorable associations in KIRP, UVM and MESO, but favorable associations in SCLC, KIRC and LIHC. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for GPR182 RNA expression.
This table summarizes GPR182 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GPR182. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR182 shows lower tumor expression in KIRC, KIRP, THCA, LIHC, UCEC and KICH. The KIRC box plot shows higher GPR182 RNA expression in normal versus tumor tissue (log2 FC = −1.710, t-test p < 0.001).
This table shows molecular features associated with GPR182 in patient tissues and cancer cell lines. In patient samples, GPR182 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR182 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
